Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q).
Saved in:
| Title: | Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q). |
|---|---|
| Authors: | Soung, Jennifer1 (AUTHOR) doctorsoung@gmail.com, Cather, Jennifer C.2,3 (AUTHOR), Gooderham, Melinda4,5,6 (AUTHOR), Ryan, Caitriona7,8 (AUTHOR), Somani, Najwa9 (AUTHOR), Feely, Meghan9,10 (AUTHOR), See, Kyoungah9 (AUTHOR), Burge, Russel9 (AUTHOR), Elrayes, Mohamed9 (AUTHOR), Gallo, Gaia9 (AUTHOR), Armstrong, April W.11 (AUTHOR) |
| Source: | JEADV Clinical Practice. Jun2023, Vol. 2 Issue 2, p282-292. 11p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
